Mangrove Partners’s Transmedics TMDX Stock Holding History

Mangrove Partners’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,764	Closed	-$215K	–	588
2025 Q4	$215K	Buy	+1,764	New	+$221K	0.02%	294

Other funds holding TMDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mangrove Partners's TMDX Position: Q1 2026 in Review

Mangrove Partners sold out of Transmedics (TMDX) in Q1 2026, closing a stake of 1,764 shares — an estimated $215K sold.

Mangrove Partners first reported a position in TMDX in Q4 2025 and held it in 1 quarter. The position peaked at $215K in Q4 2025. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

Mangrove Partners reported no remaining Transmedics position as of Q1 2026 after selling out during the quarter.
Mangrove Partners sold 1,764 Transmedics shares in Q1 2026, an estimated $215K.
Mangrove Partners first reported a position in Transmedics in Q4 2025 and held it in 1 quarter.
Mangrove Partners's Transmedics position peaked at $215K in Q4 2025.
414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.